Breaking News

You are here » Indian-Commodity  :  Top News  :  Cipla to freeze increments of around 400 top managers: Report

29-Sep2016

Cipla to freeze increments of around 400 top managers: Report

Cipla, one of India's leading generic pharmaceutical companies has reportedly decided to reduce its ballooning employee cost by freezing increments of 300-400 of its top managers as part of the company's operational revamp.  In the past five years, the company has been a laggard among its peers as management and operational changes dragged the company's profits down. For the first quarter of FY17, the company's employee cost rose by 11% to Rs 687 crore on a Y-o-Y basis, at a time when its profits had declined by 43% to Rs 365 crore.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.


Related News

View all news

Crude oil futures end higher on Friday

Crude oil futures ended higher on Friday on worries about possible impact of US sanctions on Iran's oil exports on crude supply in the market coupled with potential US-Saudi tensions. Prices also supported......

Crude oil futures extend losses on Thursday

Extending previous session losses, crude oil futures ended lower on Thursday due to a sharp jump in US crude inventories last week and on demand growth concerns. The Energy Information Administration's......

Gold futures end higher on Thursday

Gold futures ended higher on Thursday despite rising US dollar on minutes of the Federal Reserve's latest policy meeting indicating that the central bank is staying the course on interest rate hikes.Gold......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......